[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,65,107,137,174],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":4,"leadSponsor":39,"locationsCount":42},"100054882","evaluation-of-patients-with-liver-disease-100054882",false,"NCT00001971","Evaluation of Patients With Liver Disease","* INCLUSION CRITERIA:\n\nAffected Subjects\n\nIn order to be eligible to participate in this study, an affected participant must meet all of the following criteria:\n\n1. \\>=2 years of age.\n2. Meets one of the following:\n\n   1. Suspected or evidence of acute or chronic liver disease on evaluation by a referring licensed independent practitioner (LIP), OR\n   2. At risk for acute or chronic liver disease\n\nHealthy Volunteers\n\nIn order to be eligible to participate in this study, a healthy volunteer must meet all of the following criteria:\n\n1. \\>= 18 years of age.\n2. In good general health as evidenced by medical history\n\nEXCLUSION CRITERIA:\n\nAffected Participants\n\nAn affected participant who meets any of the following criteria will be excluded from participation in this study:\n\n1\\. History of significant medical illnesses that might interfere with prolonged follow up evaluation\n\nHealthy Volunteers\n\nA healthy volunteer who meets any of the following criteria will be excluded from participation in this study:\n\n1. Any chronic medical condition, including (but not limited to) heart, kidney, or lung diseases\n2. Taking any regular medications or supplements (with the exception of regular multivitamins and\u002For oral contraceptives)\n3. Average alcohol consumption \\> 1 drink\u002Fday in past 6 months, per self-report\n4. History of liver disease (with the exception of neonatal jaundice)\n5. History of severe illness, infection or major surgery in the past year\n6. History of cancer (with the exception of basal cell carcinoma resected \\> 1 year prior to enrollment)\n7. BMI \\\u003C 18 or BMI \\>25\n8. Hemoglobin \\\u003C 11 (women) or hemoglobin \\\u003C 12 (men)\n9. ALT \\>35 (men) or ALT \\>25 (women)\n10. Alkaline Phosphatase \\>= 150\n11. Bilirubin \\>2 g\u002FdL\n12. HIV positive, Anti-HCV positive, HBsAg positive or Anti-HBc positive\n13. Pregnancy\n14. Inability to provide informed consent",true,"ALL","2 Years","100 Years",{"count":20,"type":21},8050,"ESTIMATED","OBSERVATIONAL","The proposed study aims to evaluate, investigate, and follow-up patients suffering from acute and chronic liver disease. The study will focus on understanding diseases affecting the liver.\n\nPatients participating in the study will first undergo a routine check-up as an outpatient. They will be asked to provide blood and urine samples for laboratory testing and will undergo an ultrasound of the liver. Ultrasound examinations use sound waves to determine the size and texture of the liver. After the initial visit subjects will be requested to follow-up once a year at the outpatient department for a similar check-up.\n\nAdditional tests may be requested throughout the study to provide information for other research studies and individual consent will be requested. These tests may include liver biopsies, skin biopsies, and \u002F or specialized blood, plasma, and lymphocyte examinations.\n\nSubjects that qualify for medications presently being studied may be offered the opportunity to benefit from experimental therapy.",[25,26,27,28],"Hepatitis D","Hepatitis C","Hepatitis B","Liver Disease",[27,26,25,30,31,28],"Chronic Hepatitis","Natural History","RECRUITING","2026-06-27",{"date":35,"type":36},"2026-06-30","ACTUAL",{"date":38,"type":36},"1992-05-27",{"name":40,"class":41},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":15,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":42},"100645368","management-concepts-of-metabolic-dysfunction-associated-steatotic-liver-disease-masld-among-chinese-physicians-100645368","NCT07682363","Management Concepts of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Among Chinese Physicians","Attitudes, Perceptions, Clinical Practice, and Barriers in Diagnosis and Management of Patients With Metabolic Dysfunction-associated Steatotic Liver Disease: a Cross-sectional Survey on Physicians in China","Inclusion Criteria:\n\n* Has provided informed consent.\n* Registered clinical practice location in provincial capital or municipality.\n* Physician with a license for clinical practice.\n* Employed in the Department of Endocrinology, Hepatology, Infection or Gastroenterology.\n* Hospital level: Grade IIIA hospital.\n* Hold a professional title of associate chief physician or above, or senior attending physician (as an attending physician for more than or equal to (≥) 3 years).\n* Conducts outpatient clinics for at least 1 half-days per week.\n* The patient load of MASLD\u002FMASH per month in the department should be:\n* a. Endocrinology ≥20 patients per month\n* b. Hepatology\u002FGastroenterology\u002F Infectious ≥30 patients per month\n\nExclusion Criteria:\n\n-Participants will be excluded if they have unwillingness precluding adequate cooperation, fail to complete the questionnaire, or submit questionnaires verified as invalid.","18 Years",{"count":52,"type":21},470,"This study is a cross-sectional survey-based study. The main goal of this study is to investigate the attitudes, perceptions, and clinical practice in assessing liver fibrosis following a metabolic dysfunction-associated steatotic liver disease (MASLD) diagnosis, and the management of MASLD patients among Chinese physicians in the departments of endocrinology \u002F hepatology \u002F infection \u002F gastroenterology in Grade IIIA hospitals in provincial capitals or municipalities.",[28],"2026-06-26",{"date":57,"type":36},"2026-07-02",{"date":59,"type":36},"2026-06-03",{"date":61,"type":21},"2027-02-23",{"name":63,"class":64},"Novo Nordisk A\u002FS","INDUSTRY",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":5},"100508347","online-prehabilitation-for-patients-awaiting-liver-transplantation-100508347","NCT05899231","Online Prehabilitation for Patients Awaiting Liver Transplantation","OPAL: Online Prehabilitation for Patients Awaiting Liver Transplantation - a Multicenter Randomized Controlled Trial to Reduce Physical Frailty and Improve Health Outcomes","OPAL","Inclusion Criteria:\n\n≥18 years old with cirrhosis (confirmed with transient elastography by FibroScan, histology, or imaging-based assessment with compatible clinical picture), referred for transplant and are assessed to have a high likelihood of being listed according to a preliminary review by hepatologist or are already listed for LT, are pre-frail or frail on the liver frailty index (LFI) or (added August 30, 2024) pre-frail or frail on the TeLeFI (prefrail LFI 3.2-4.3 and frail LFI ≥4.4), have English or French language proficiency, and own an internet-connected device.\n\nExclusion Criteria:\n\n* Listed for living related donor transplantation with expected time on the wait list \\\u003C12 weeks, or model for end-stage liver disease (MELD-Na) Score \\>26 (Justification: time to transplant is very short)\n* Robust status on frailty testing (LFI 0-3.1) (Justification: unlikely to see benefit)\n* Unable to provide informed consent\n* Presence of a clinical condition that makes the intervention unsafe or infeasible (e.g. unable to follow instruction) or unsafe environment for virtual participation\n* Life expectancy less than 6 months, compassionate care (clinician judgment) (Justification: unlikely to see benefit)\n* Recent variceal bleed or history of varices not on adequate prophylaxis (Justification: acute exercise increases portal pressure\n* Transplant indication is cholangiocarcinoma.",{"count":74,"type":21},177,"INTERVENTIONAL",[77],"NA","Physical frailty is common in patients awaiting liver transplantation and has been associated with poor health outcomes. There is promising data from small studies showing that behavioural, nutrition, exercise therapy (prehabilitation) improves physical function in patients while they are waiting for a liver transplant.\n\nThe proposed trial will assess if a 12-week online prehabilitation program improves physical function in patients listed for liver transplantation. Over 4 years, 177 patients will be recruited from 6 transplant centres across Canada and will be randomized to receive either the online prehabilitation program or usual care.\n\nThe primary outcome of physical function will be evaluated using the FTSST at baseline and 12 weeks (or last timepoint before transplant) assessed virtually or in-person. Secondary outcomes include liver specific physical frailty, aerobic fitness, health-related quality of life (QoL), participant experience and acceptability. Exploratory outcomes include other virtual and in-person physical function measures, covert hepatic encephalopathy (CHE), sarcopenia, malnutrition, adherence, behaviour factors, clinical and post-transplant outcomes. Results will be compared between the intervention and usual care groups.",[80,81,28],"Cirrhosis, Liver","Liver Transplant Surgery",[83,84,85,86,87,88,89,90,91,92,93,94,95,96],"frailty","transplant","nutrition","exercise","ehealth","application","wellness","prehabilitation","sarcopenia","malnutrition","physical function","digital","virtual","online","2026-04-07",{"date":99,"type":36},"2026-04-08",{"date":101,"type":36},"2023-07-12",{"date":103,"type":21},"2026-09",{"name":105,"class":106},"University of Alberta","OTHER",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":115,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100622045","cobas-lumira-collection-of-venous-and-capillary-blood-samples-for-the-research-optimization-and-calibration-of-new-diagnostic-devices-100622045","NCT07378514","Cobas® Lumira Collection of Venous and Capillary Blood Samples for the Research, Optimization and Calibration of New Diagnostic Devices","Cobas® Lumira Collection of Venous and Capillary Blood Samples for the Research, Optimization and Calibration of New Diagnostic Devices (EVOLVE)","EVOLVE","Inclusion Criteria:\n\n1. Willing and able to provide written informed consent.\n2. Willing to comply with study procedures.\n3. The participant must present as one of the following cohorts (primary presenting condition):\n\n   * Cohort A - Embolism Cohort (participants presenting with symptoms indicative of thromboembolic events)\n   * Cohort B - Infection or Inflammation Cohort (participants presenting with symptoms indicative of infection or inflammatory disorders)\n   * Cohort C - Cardiovascular Cohort (participants presenting with symptoms indicative of heart failure or acute coronary syndrome)\n   * Cohort D - Renal Cohort (participants presenting with symptoms indicative of renal disorders)\n   * Cohort E - Oral Anticoagulation Cohort (participants with ongoing vitamin K antagonist therapy for at least four weeks)\n   * Cohort F - Diabetes Cohort (participants with suspected pre-Diabetes or diagnosed with Diabetes Mellitus Type 1 or Type 2)\n   * Cohort G - Lipid Cohort (participants presenting with symptoms indicative for Hypercholesterolemia )\n   * Cohort H - Liver Cohort (participants with symptoms indicative of hepatic disorders).\n\nInclusion Criteria for Cohorts A, B, C, D, E, G, and H:\n\n1\\. Participants ≥ 18 years of age\n\nInclusion Criteria for Cohort F (Diabetes Cohort):\n\n1\\. Participants ≥ 16 years old\n\nExclusion Criteria:\n\n1. Subjects deemed inappropriate for the study by the Principal Investigator.\n2. Participants who have previously been enrolled in the EVOLVE study in the past 60 days.\n\nExclusion Criteria for Cohort E (Oral Anticoagulation Cohort):\n\n1. Subjects who are currently taking non-vitamin K antagonist oral anticoagulants (NOACs) including but not limited to apixaban, dabigatran etexilate, edoxaban and rivaroxaban.\n2. Subjects who have anti-phospholipid antibody syndrome (APS)\n3. The participant is currently receiving or has received within the past thirty (30) days of the study visit an experimental biologic, experimental drug, or experimental device including either treatment or therapy.","16 Years",{"count":117,"type":21},30000,"This study is a blood sample collection study, collecting venous and capillary blood samples from adult patients in the UK, with a range of health conditions. The purpose of this study is to collect blood samples to help develop, improve, and fine-tune new and existing diagnostic tests for the cobas® lumira instrument. This instrument is a diagnostic medical device with single-use test strips, that allows diagnostic testing right at the patient's side. The aim is to improve doctors' ability to monitor health conditions more quickly and easily.\n\nApproximately 30,000 patients are expected to participate in this study, across multiple UK sites.",[120,121,122,123,124,125,126,28],"Blood Clots","Infection and Inflammatory Reaction","Heart Disease","Kidney Disease","Vitamin K Antagonist","Diabetes","High Cholesterol","NOT_YET_RECRUITING","2026-01-22",{"date":130,"type":36},"2026-01-30",{"date":132,"type":21},"2026-04",{"date":134,"type":21},"2031-07",{"name":136,"class":64},"LumiraDx UK Limited",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":145,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":75,"phases":149,"briefSummary":150,"conditions":151,"keywords":154,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":42},"100595427","digital-behavioral-therapy-to-reduce-diabetes-and-liver-disease-risk-100595427","NCT07032311","Digital Behavioral Therapy to Reduce Diabetes and Liver Disease Risk","Effect of Behavioral Intervention\u002FTherapy to Reduce Diabetes and Liver Disease Risk Through Prescribed Digital Therapeutics Enabled by AI\u002FML Powered Predictive Analytics","SIPPA-QH_HHC-2","Inclusion Criteria:\n\n* English Proficiency with a Middle-school Reading Level\n* Owning a smartphone or obtaining one on-loan basis during the study period, with a data plan and\u002For the ability to receive text messages\n* Possess basic skills to operate an (Android) smartphone, if you want to receive behavior intervention\u002Ftherapy in addition to the standard care service\n* Willingness to Modify Behavior, Physical activity, and diet\n* Age 22 to 65\n* Diagnosed with diabetes and prediabetes with two or more blood work results since 2021 revealing alanine aminotransferase (ALT), aspartate aminotransferase (AST), and platelet count (ICD-10 code; Prediabetes: R73.03, Diabetes: E08-E13); whereas prediabetes is clinically defined as two consecutive measure of A1C between 5.8 and 6.5\n* Willing to communicate with the project team via phone, email, or SMS once a week\n\nExclusion Criteria:\n\nConsume more than one and a half times the limit of alcohol recommended for the population (15g\u002Fday for women and 30 g\u002Fday for men) (ICD-10 code: K70.9)\n\n* Pregnancy (ICD-10 code: Z33.3)\n* Receiving Hepatotoxic Medication (ICD-10 code: K76.1)\n* Cirrhosis, Hepatitis B\u002FC, and Other Chronic Liver Diseases (ICD-10 code: K.74, B19.10, B19.20, K72.1)\n* Cardiovascular Events in the Past 6 Months and Symptomatic Heart Failure (ICD-10 code: I.21, I.25, I.50, I63.9)\n* Stage 4 and Above Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD)(ICD-10 code: N18.4, N18.5, N18.6)\n* Untreated Hypothyroidism (ICD-10 code: E03.9)\n* Depression (ICD-10 code: F32.A)\n* A patient who already received a digital behavioral intervention\u002Ftherapy prescribed by a clinician is ineligible for this study for safety considerations.","22 Years","65 Years",{"count":148,"type":21},200,[77],"This clinical trial aims to find out if a digital behavioral program, delivered through the SIPPA digital therapeutics app, can help improve blood sugar control and lower the risk of liver fibrosis in adults with type 2 diabetes who are at low to moderate risk for liver disease.\n\nMain Research Question:\n\nCan adding the SIPPA behavioral program to standard diabetes care lower HbA1c (a marker of blood sugar control) more than standard care alone?\n\nStudy Design:\n\nThe study has two groups (called \"arms\") for comparison:\n\nArm 1: Control Group Subgroup 1.1: Participants receiving standard care without GLP-1 medication. Subgroup 1.2: Participants receiving standard care with GLP-1 medication.\n\nArm 2: Intervention Group Subgroup 2.1: Participants receiving standard care without GLP-1 medication, plus the SIPPA behavioral program.\n\nSubgroup 2.2: Participants receiving standard care with GLP-1 medication, plus the SIPPA behavioral program.\n\nResearchers will compare outcomes across the matched groups in each arm to evaluate the impact of the SIPPA program.\n\nWhat Participants Will Do:\n\nAll participants will have lab tests at the start of the study, at 3 months, and at 6 months. These tests include:\n\n* HbA1c (a measure of average blood sugar levels),\n* Fib-4 score (used to estimate liver fibrosis risk), and\n* Liver enzyme tests.\n\nParticipants in the intervention group (Arm 2) will also:\n\n* Use the SIPPA app daily to complete behavioral modules, track blood sugar\n* levels, and log health behaviors (like diet and activity).\n* Have weekly check-ins with a health navigator to support progress and stay on track with their diabetes treatment plan.",[152,153,28],"Type 2 Diabetes","Prediabetes",[155,153,156,157,158,159,160,161,162,163,164],"Type 2 diabetes mellitus","Digital therapeutics","Behavioral intervention","Smartphone app","GLP-1 receptor agonist","Fib-4 score","Randomized pilot trial","Metabolic dysfunction-associated steatotic liver disease (MASLD)","Health navigator support","SIPPA Health","2025-06-19",{"date":167,"type":36},"2025-06-23",{"date":169,"type":21},"2025-07-01",{"date":171,"type":21},"2027-06-30",{"name":173,"class":64},"SIPPA Solutions INC",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":75,"phases":183,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":42},"100363607","safety-and-efficacy-of-fecal-microbiota-transplantation-100363607","NCT04014413","Safety and Efficacy of Fecal Microbiota Transplantation","Safety and Efficacy of Fecal Microbiota Transplantation: A Pilot Study","Inclusion Criteria:\n\nConfirmed diagnosis of any of the following diseases:\n\n* Crohn's disease\n* Ulcerative colitis\n* Celiac disease\n* Irritable bowel syndrome\n* Functional dyspepsia\n* Constipation\n* Antibiotic-associated diarrhea or any antibiotic- associated complications\u002Fsymptoms\n* Metabolic syndrome such as diabetes mellitus and obesity\n* Multidrug-resistant infection\n* Hepatic encephalopathy\n* Multiple sclerosis\n* Pseudo-obstruction\n* Carbapenem-resistant Enterobacteriaceae (CRE) or Vancomycin-resistant Enterococci (VRE) infection\n* Multiple organ dysfunction\n* Dysbiotic bowel syndrome\n* MRSA enteritis\n* Pseudomembranous enteritis\n* Alopecia, autism\n* Graft-versus-host disease\n* Idiopathic thrombocytopenic purpura (ITP)\n* Atopy or allergy\n* Liver disease such as Nonalcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH)\n* Alcohol dependence\n* Psoriatic arthropathy that has suboptimal control of disease despite standard treatment.\n\nExclusion Criteria:\n\n* Known contraindication to all FMT infusion method such as nasoduodenal tube insertion, oesophago-gastro-duodenoscopy (OGD), enteroscopy, colonoscopy and enema\n* Any conditions that may render the efficacy of FMT or at the discretion of the investigators\n* Current pregnancy",{"count":182,"type":21},450,[77],"The gut microbiota is critical to health and functions with a level of complexity comparable to that of an organ system. Dysbiosis, or alterations of this gut microbiota ecology, have been implicated in a number of disease states. Fecal microbiota transplantation (FMT), defined as infusion of feces from healthy donors to affected subjects, is a method to restore a balanced gut microbiota and has attracted great interest in recent years due to its efficacy and ease of use. FMT is now recommended as the most effective therapy for CDI not responding to standard therapies.\n\nRecent studies have suggested that dysbiosis is associated with a variety of disorders, and that FMT could be a useful treatment. Randomized controlled trial has been conducted in a number of disorders and shown positive results, including alcoholic hepatitis, Crohn's disease (CD), ulcerative colitis (UC), pouchitis, irritable bowel syndrome (IBS), hepatic encephalopathy and metabolic syndrome. Case series\u002Freports and pilot studies has shown positive results in other disorders including Celiac disease, functional dyspepsia, constipation, metabolic syndrome such as diabetes mellitus, multidrug-resistant, hepatic encephalopathy, multiple sclerosis, pseudo-obstruction, carbapenem-resistant Enterobacteriaceae (CRE) or Vancomycin-resistant Enterococci (VRE) infection, radiation-induced toxicity, multiple organ dysfunction, dysbiotic bowel syndrome, MRSA enteritis, Pseudomembranous enteritis, idiopathic thrombocytopenic purpura (ITP), and atopy.\n\nDespite FMT appears to be relatively safe and efficacious in treating a wide range of disease, its safety and efficacy in a usual clinical setting is unknown. More data is required to confirm safety and efficacy of FMT. Therefore, the investigators aim to conduct a pilot study to investigate the efficacy and safety of FMT in a variety of dysbiosis-associated disorder.",[186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,28,210,211],"Crohn Disease","Ulcerative Colitis","Celiac Disease","Irritable Bowel Syndrome","Functional Dysphonia","Constipation","Clostridium Difficile Infection","Diabetes Mellitus","Obesity","Multidrug -Resistant Infection","Hepatic Encephalopathy","Multiple Sclerosis","Pseudo-Obstruction","Carbapenem-Resistant Enterobacteriaceae Infection","Vancomycin Resistant Enterococci Infection","Multiple Organ Dysfunction Syndrome","Dysbiotic Bowel Syndrome","MRSA Enteritis","Pseudomembranous Enterocolitis","Alopecia","Autism","Graft-versus-host Disease","Idiopathic Thrombocytopenic Purpura","Atopy or Allergy","Alcohol Dependence","Psoriatic Arthropathy","2024-08-21",{"date":214,"type":36},"2024-08-22",{"date":216,"type":36},"2019-07-15",{"date":218,"type":21},"2030-10-31",{"name":220,"class":106},"Chinese University of Hong Kong"]